GSK · US market

GLAXOSMITHKLINE

Compare this company’s P/E and P/S using trailing results and the latest quarter. Ratios are calculated here from market capitalisation, signed ordinary or common-shareholder earnings and revenue.

Market cap US$101.80bnFinancials dated 31 March 2026Price dated 1 October 2026

Core valuation

Trailing P/E13.11×
Latest-quarter run-rate P/E10.99×
Trailing P/S2.33×
Latest-quarter run-rate P/S2.50×

Calculation inputs

Trailing earnings
US$7.77bn
Latest-quarter run-rate earnings
US$9.26bn
Latest fiscal-year earnings
US$7.62bn
Trailing revenue
US$43.68bn
Latest-quarter run-rate revenue
US$40.67bn
Latest fiscal-year revenue
US$43.53bn

Featured ETF and mutual-fund exposure

These public funds report this company in their latest disclosed holdings.

Sources and limitations

Financial inputs are attributed to Issuer financial results. Market cap is calculated locally where auditable price and share inputs are available. Missing data stays missing; losses are retained as signed values and produce a numeric signed P/E.

Open financial source

Financials as of 31 March 2026. Informational research, not investment advice.